MDS 2023 | The role of inflammation in MDS & the potential to target it to prevent and treat MDS
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, comments on the role of inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Prof. Mittelman highlights that many immune disorders are associated with MDS and cites a study from his research group identifying elevated levels of inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in patients with MDS compared to controls. Prof. Mittelman also comments on the link between aging and inflammation in MDS, and concludes by highlighting the potential of anti-inflammatory agents to prevent MDS development or progression. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
